Altimmune (ALT) Assets Average (2011 - 2026)
Altimmune (ALT) posted quarterly Assets Average of $307.8 million for Q1 2026, up 107.56% year-over-year from $148.3 million in Q1 2025, and up 23.51% quarter-over-quarter from $249.2 million in Q4 2025.
Altimmune (ALT) Assets Average (2011 - 2026) Analysis & Trends
Altimmune (ALT) has reported Assets Average for 16 consecutive years, with $307.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 107.56% year-over-year to $307.8 million; the TTM figure through Mar 2026 stood at $307.8 million (up 107.56% YoY), while the FY2025 annual figure was $209.6 million, up 19.8% from the prior year.
- Assets Average improved to $307.8 million in Q1 2026 per ALT's latest filing, from $249.2 million in the prior quarter.
- Across five years, Assets Average topped out at $307.8 million in Q1 2026 and bottomed at $143.6 million in Q4 2024.
- Historically, Assets Average has averaged $198.1 million across 5 years, with a median of $197.0 million in 2023.
- Annual changes were most pronounced in 2025 — Assets Average fell 25.67% — and 2026, when it soared 107.56%.
- Altimmune's Assets Average stood at $216.1 million in 2022, then dropped by 12.72% to $188.6 million in 2023, then decreased by 23.87% to $143.6 million in 2024, then soared by 73.55% to $249.2 million in 2025, then gained by 23.51% to $307.8 million in 2026.
- Business Quant data shows ALT's Assets Average at $307.8 million in Q1 2026, $249.2 million in Q4 2025, and $204.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Altimmune | 571.75 Mn | 571.75 Mn | - | 431.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 431.42 Mn |
| Mar 31, 2026 | 307.78 Mn |
| Dec 31, 2025 | 249.19 Mn |
| Sep 30, 2025 | 204.40 Mn |
| Jun 30, 2025 | 173.81 Mn |
| Mar 31, 2025 | 148.28 Mn |
| Dec 31, 2024 | 143.59 Mn |
| Sep 30, 2024 | 160.61 Mn |
| Jun 30, 2024 | 180.85 Mn |
| Mar 31, 2024 | 199.50 Mn |
| Dec 31, 2023 | 188.61 Mn |
| Sep 30, 2023 | 174.94 Mn |
| Jun 30, 2023 | 185.20 Mn |
| Mar 31, 2023 | 197.01 Mn |
| Dec 31, 2022 | 216.10 Mn |
| Sep 30, 2022 | 217.59 Mn |
| Jun 30, 2022 | 207.78 Mn |
| Mar 31, 2022 | 212.26 Mn |
| Dec 31, 2021 | 227.89 Mn |
| Sep 30, 2021 | 247.08 Mn |